Innate Pharma, Novo Nordisk deal

Following a February decision to refocus their 2003 deal on inflammation, the partners assigned to Innate exclusive, worldwide rights to develop and commercialize IPH 2101 ( NN1975), the lead cancer compound under the deal. In return, Innate will pay Novo € 2.5 million ($3.4 million) up front, plus potential milestones and royalties. Innate also will forgo the milestones and royalties it would have been eligible to receive for IPH 2301 ( NN8555), the lead inflammation compound under the deal. IPH 2101 is a human IgG4 mAb in Phase I testing to treat acute myelogenous leukemia (AML) and multiple myeloma (MM). IPH 2301 is a mAb against NK and T cells in preclinical testing to treat major chronic inflammatory and autoimmune conditions. ...